Scientists at Rutgers University-New Brunswick have developed Tourette trait mice using advanced genetics, a breakthrough that could lead to personalized treatments for Tourette disorder. The researchers utilized CRISPR/Cas9 DNA editing to insert genetic mutations found in humans with Tourette disorder into mouse embryos, resulting in mice that display similar behaviors and brain abnormalities as humans with the disorder. This model will be instrumental in studying the neurobiology of Tourette disorder and testing new medications.
Tourette disorder is a neurological condition characterized by involuntary movements or sounds known as tics. The genetically engineered mice exhibited repetitive motor behaviors and sensorimotor gating deficits, similar to humans with the disorder. By altering the levels of dopamine in the mice’s brains with medication, the researchers observed a decrease in processing deficits and repetitive behaviors.
The study, published in the Proceedings of the National Academy of Sciences, sheds light on the genetic factors underlying Tourette disorder and provides a platform for developing effective treatments. The researchers emphasized the importance of families with Tourette disorder who contributed genetic samples to advance the understanding of the condition. This research not only benefits current individuals with Tourette disorder but also paves the way for future generations.
The findings from this study may also have implications for other complex disorders caused by multiple genes, such as autism and schizophrenia. By creating a mouse model for Tourette disorder, researchers now have a valuable tool to investigate the underlying mechanisms of the condition and develop targeted therapies. This innovative approach could attract more researchers to study Tourette disorder and potentially uncover new avenues for treatment.
The work done by the researchers at Rutgers University-New Brunswick represents a significant step forward in the field of Tourette disorder research. Their findings have the potential to transform the treatment landscape for individuals with the disorder and provide hope for a better understanding of its underlying causes.
